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rats. Intraperitoneal administration of chemical carcinogen diethyl nitrosamine (DENA) (200 mg/
kg) in single dose elevated the levels of serum glutamate oxaloacetate transaminase (SGOT), serum
glutamate pyruvate transaminase (SGPT), alkaline phosphatase (ALP), total cholesterol (TC), tri-
glycerides (TG) and reduced high density lipoproteins (HDL), total proteins (TPR) and blood glucose
level in tested animals. Histopathological examinations of the liver tissue showed marked carcinoge-
nicity of the chemical carcinogen. Food and water intake, animal weights and serum albumin (ALB)
were also assessed. The animals exposed to DENA showed a signiﬁcant decrease in the body weights
and, there were no signiﬁcant alterations found in the total bilirubin (TBR) levels and gamma-glutam-
yltranspeptidase (GGTP), whereas the decreased levels of serumALBwere maintained byMetformin
treatment. The elevated levels of serum SGOT, SGPT, ALP, AFP, TC and TG were restored by
administration of Metformin in reduced dose (125 mg/kg) daily for 16 weeks p.o. Physiological and
biochemical analysis showed the beneﬁcial effects of Metformin in the animals exposed to DENA.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.hartha Institute of Pharmacy,
01, Uttarakhand, India. Tel.:
.
oo.com (F. Anwar).
y. Production and hosting by
Saud University.
lsevier1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth leading cause of
cancer worldwide and its incidence is constantly increasing
day by day (Parkin et al., 2001). The largest concentration of pa-
tients is in Asia and sub-Saharan countries (Hollstein et al.,
1993). Treatments for HCC include liver transplantation, resec-
tion, local ablative therapy, hepatic artery transcatheter treat-
ment, and systemic treatment. Surgical therapy is the only
potentially curative treatment for HCC, but nonsurgical treat-
ment can prolong the survival period and palliate symptoms
(Llovet et al., 2003). The median survival of HCC is less than
366 M. Afzal et al.12 months from diagnosis, reﬂecting both late presentation and
lack of effective therapy (Groupe d’Etude et al., 1995).Given the
time course of the disease and the burden of treatment, there is
an increase in concerns about the liver diseases and HCC. Met-
formin is an oral antihyperglycemic agent commonly used in
non-insulin dependent (type 2) diabetes mellitus (Klepser and
Kelly, 1997). It works by decreasing Gluconeogenesis and acti-
vatingAMP-activated protein kinase pathway (Lee, 1996).Met-
formin has been proved by numerous authors as an anticancer
agent in lung cancer, breast cancer and ovarian cancer (Esfaha-
nian et al., 2012;Del Barco et al., 2011;Goodwin and Stambolic,
2011; Monteagudo et al., 2011; Schott et al., 2011; Guppy et al.,
2011). Several potential mechanisms have been suggested and
established for the ability of Metformin to suppress cancer
growth in vitro and in vivo: (1) activation of LKB1/AMPK
pathway, (2) induction of cell cycle arrest and/or apoptosis,
(3) inhibition of protein synthesis, (4) reduction in circulating
insulin levels, (5) inhibition of the unfolded protein response
(UPR), (6) activation of the immune system, and (7) eradication
of cancer stem cells to name a few (Kourelis and Siegel, 2011).
Evaluation ofMetformin in the treatment of hepatocarcinogen-
esis, is a novel approach in the ﬁeld of chemotherapy. The pres-
ent study will help and assist to design proper medication for
patients suffering from diabetes and hepatic cancer.
2. Materials and methods
2.1. Drugs and chemicals
Metformin was provided as a gift sample from Windlass
Health Care, Dehradun; DENA was procured from Sigma–Al-
drich Chemicals Co., St. Louis, USA and Chloroform and
Diethyl ether from S.D. Fine Chem. Ltd., Mumbai. All the
chemicals were of analytical grade.
2.2. Animals
Adult, healthy, male Wistar albino rats weighing 100–125 g
were procured from the animal house facility of Siddhartha
Institute of Pharmacy for the present protocol. The rats were
housed in groups in polypropylene cages under controlled con-
ditions of temperature (22 + 3 C) and light (14:10 h light and
dark cycle) and provided with balanced pallet diet and water
ad libitum. The protocol was approved by the Institutional
Animal Ethics Committee (IAEC) as per the guidance of the
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA); Ministry of Social Justice
and Empowerment, Government of India.
2.3. Induction of hepatocarcinoma
Liver cancer was induced by a carcinogenic dose of 200 mg/kg
body weight, I.P. DENA when associated with fasting/refeed-
ing (Alwahaibi et al., 2010; Gonul et al., 1996; Muzio et al.,
1999; Xu-yinga et al., 2009).
2.4. Experimental design
The rats were acclimatized and randomly divided into ﬁve
groups each having 6 rats for a 16 week study. Group-I ratsserved as vehicle control and were treated with saline orally.
Group-II rats were administered a single dose of DENA
(200 mg/kg), Group-III rats were administered Metformin
(125 mg/kg) from day 1 and after 7th day DENA (200 mg/
kg) was administered. Group-IV rats were treated with DENA
(200 mg/kg) and after 7th day Metformin treatment (125 mg/
kg) was initiated. Group-V rats were treated with Metformin
(125 mg/kg) as a control. The dose of Metformin was selected
by performing an effective dose ﬁxation study.
2.5. Estimation of biochemical parameters
Blood samples were collected on the termination day of the
experiment from the retro-orbital plexus under light ether
anesthesia without any anticoagulant and were allowed to
stand for 30 min at room temperature, centrifuged at
2500 rpm for 10 min to separate the serum. The serum ob-
tained was kept at 2–4 C for further use. The blood glucose
level was measured using a digital glucometer (Abbott Dia-
betes care Inc., Alameda, USA). A drop of blood was
placed on one side of a test strip that was inserted in the
glucometer. The glucose level was displayed onto the screen
within 20 s. Estimation of serum SGOT, SGPT, ALP,
GGTP, TC, TG, HDL, blood glucose, TPR, TBR and
ALB was performed using standard kits (Nicholas India
Pvt. Ltd.) with semi-auto analyzer (photometer 5010, Nich-
olas India Pvt. Ltd.). Serum a-feto protein (AFP) was esti-
mated by the method described by Premalatha and
Sachdanandam (1999).
2.6. Histopathological examination
The liver samples were preserved in phosphate-buffered 10%
formalin, embedded in parafﬁn and used for histopathological
examination. Five-lm-thick sections were cut, deparafﬁnized,
hydrated and stained with hematoxylin and eosin. The sections
were examined blindly for tubular cell swelling, interstitial ede-
ma, tubular dilatation, and moderate to severe necrosis in all
treatments.
2.7. Statistical analysis
The results were expressed as mean ± SEM. Statistical signif-
icance between more than two groups was tested using one-
way ANOVA followed by the Bonferroni multiple comparison
test or an unpaired two-tailed student’s t-test as appropriate
using a computer based ﬁtness program (Prism, Graphpad).
Differences were considered to be statistically signiﬁcant
(p< 0.05).
3. Results
3.1. Animal weight
DENA control group showed signiﬁcant reduction in body
weight as compared to a normal control group. In PMTG,
the body weight decreased when compared to DENA con-
trol. Metformin group also showed the signiﬁcant reduction
in the body weight when compared to vehicle controls
(Table 1).
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DENA control animals exhibited signiﬁcantly decreased
(p< 0.01) TPR levels as compared to a vehicle control.
PMTG and MTG groups exhibited signiﬁcantly increased
(p< 0.001) TPR levels when compared to the DENA control.
Metformin group exhibited signiﬁcantly decrease in (p< 0.01)
TPR levels as compared to a vehicle control (Table 1).
3.3. Blood glucose
DENA control group showed signiﬁcantly decreased
(p< 0.001) glucose level than normal controls. The blood glu-
cose level in the PMTG and MTG group was signiﬁcantly al-
tered (p< 0.001) when compared to DENA control.
Metformin control exhibited the signiﬁcant decrease
(p< 0.001) in blood glucose level as compared to a vehicle
control (Table 1).
3.4. Liver proﬁle study
3.4.1. Serum glutamate pyruvate transaminase (SGPT/ALT)
The DENA control exhibited signiﬁcantly elevated (p< 0.001)
level of SGPT as compared to a vehicle control, while PMTG
and MTG groups showed signiﬁcant decrease in (p< 0.001)
SGPT levels as compared to the DENA control. Metformin
control showed the signiﬁcantly decreased (p< 0.001) SGPT
level as compared to a vehicle control (Table 2).
3.4.2. Serum glutamate oxaloacetate transaminase (SGOT/
AST)
SGOT level was signiﬁcantly increased (p< 0.001) in DENA
control as compared to vehicle control. The PMTG and
MTG groups exhibited signiﬁcant decrease in (p< 0.001)
SGOT levels when compared with the DENA control. Metfor-
min control exhibited signiﬁcant decrease (p< 0.001) in
SGOT level as compared to a vehicle control (Table 2).
3.4.3. Serum alkaline phosphatase (SALP)
PMTG and MTG groups exhibit a signiﬁcant decrease in
(p< 0.001) SALP levels as compared to DENA control
(Table 2).
3.4.4. Gamma-glutamyltranspeptidase (GGTP)
DENA controls did not show any signiﬁcant alteration in the
GGTP level as compared to vehicle control. In PMTG groupTable 1 Effect of various pharmacological interventions on body w
S. no. Groups Body weight (g) Total pro
1 Vehicle control 127.11 ± 2.71 7.60 ± 0
2 DENA control 117.23 ± 2.13 3.63 ± 0
3 MTG 079.83 ± 3.21 4.78 ± 0
4 PMTG 123.26 ± 3.77 4.83 ± 0
5 Metformin 072.18 ± 2.01 5.83 ± 0
Values are expressed as mean ± SEM (N= 6). MTG=Metformin thera
a p< 0.001, as compared to vehicle control.
b p< 0.01as compared to DENA control.
** p< 0.01, as compared to vehicle treated group.
*** p< 0.001, as compared to vehicle treated group.GGTP level was signiﬁcantly increased (p< 0.05) when com-
pared to DENA control. There were no signiﬁcant changes in
GGTP level in the Metformin control as compared to a vehicle
control (Table 2).
3.4.5. Total bilirubin (TBR)
There was no signiﬁcant alteration found in the TBR levels in
all groups.
3.4.6. Albumin (ALB)
In DENA control group the ALB level was signiﬁcantly de-
creased (p< 0.001) as compared to vehicle control whereas
PMTG and MTG treatment with Metformin signiﬁcantly in-
creased (p< 0.01) ALB levels. In the Metformin control the
ALB level was signiﬁcantly decreased (p< 0.001) as compared
to a vehicle control (Table 2).
3.5. Lipid proﬁle
Signiﬁcant elevation in the levels of TC and TG and reduction
in HDL were observed in the animals exposed to DENA when
compared to a normal control. These parameters were main-
tained to normal by the treatment of Metformin in both the
PMTG, MTG groups and Metformin control groups (see
Table 3).
3.6. Serum a-feto protein (AFP)
The level of AFP in serum was signiﬁcantly (p< 0.05) in-
creased in DENA treated rats when compared to vehicle con-
trol, whereas their levels remained near the control in animals
treated with Metformin (Table 2).
3.7. Histopathological study
Liver sections from the control group showed normal liver his-
tology with unremarkable central veins, no evidence of hepato-
cyte injury or ﬁbrosis or dysplasia or malignancy noticed.
Disease control animals showed central veins surrounded by
extensive necrosis and inﬂammatory inﬁltrate, clusters of hepa-
tocyte necrosis and the portal tract with bile duct proliferation
and marked atypia. The tumor cells resembling hepatocytes
show pleomorphism and are seen as 2–8 cell wide trabeculae
that are separated by endothelium lined sinusoidal spaces.
The prophylactic group showed periportal inﬂammation with
conspicuously dilated blood vessels and ballooning degenera-eights, total proteins and blood glucose of animals.
tein (mg/dl) Blood glucose (mg/dl) ALB (mg/dl)
.42 62.83 ± 0.70 4.01 ± 0.02
.20a/** 50.33 ± 1..33a/*** 2.16 ± 0.06a/***
.31b/*** 36.60 ± 0.54b/*** 2.98 ± 0.09b/**
.32b/*** 32.78 ± 1.292b/*** 2.61 ± 0.14b/**
.30a/** 53.67 ± 1.14a/*** 3.61 ± 0.21a/***
peutic group and PMTG= prophylactic metformin treatment group.
Table 3 Effect of metformin on serum lipid proﬁle.
S. no. Groups TC (mg/dl) TG (mg/dl) HDL (mg/dl)
1 Vehicle control 093.25 ± 2.74 36.19 ± 0.60 30.71 ± 0.44
2 DENA control 035.50 ± 3.24b/*** 95.23 ± 1.14 a/** 10.51 ± 0.54 a/***
3 MTG 104.5 ± 2.40a/*** 55.67 ± 2.42 b/*** 03.66 ± 1.0 b/***
4 PMTG 033.67 ± 4.13a/*** 84.61 ± 2.91a/** 13.84 ± 1.42 b/***
5 Metformin 030.52 ± 1.3b/*** 93.15 ± 1.38a/*** 19.17 ± 1.42a/**
Values are expressed as mean ± SEM (N= 6).
a p< 0.001, as compared to normal control.
b p< 0.01 as compared to DENA control.
** p< 0.01, as compared to vehicle treated group.
*** p< 0.001, as compared to vehicle treated group.
Table 2 Effect of metformin on serum SGOT, SGPT, ALP, GGTP and TB of animals.
S. no. Treatment SGPT (mg/dl) SGOT (mg/dl) ALP (mg/dl) GGPT (mg/dl) Total bilirubin (mg/dl) AFP (mg/dl)
1 Vehicle control 050.33 ± 0.33 53.33 ± 1.054 05.83 ± 0.30 1.66 ± 0.09 0.55 ± 0.02 22.04 ± 0.78
2 DENA control 075.01 ± 1.55a/*** 76.13 ± 1.764a/*** 10.33 ± 0.33a/*** 2.33 ± 0.11ns 1.41 ± 0.67ns 297.11 ± 35.12b/***
3 MTG 100.51 ± 1.01b/*** 63.17 ± 1.13b/*** 06.83 ± 0.60b/*** 1.16 ± 0.66b/* 0.45 ± 0.04ns 48.23 ± 1.29a/***
4 PMTG 071.15 ± 0.85ns 50.33 ± 0.95b/*** 05.83 ± 0.60b/*** 1.59 ± 0.04ns 0.43 ± 0.05ns 63.99 ± 1.56a/***
5 Metformin 038.50 ± 1.360a/*** 41.35 ± 2.2a/*** 02.65 ± 0.33a/*** 0.69 ± 0.07ns 0.11 ± 0.01ns 19.22 ± 0.89b/*
Values are expressed as mean ± SEM (N= 6).
a p< 0.001, as compared to normal control.
b p< 0.01as compared to DENA control.
* p< 0.05, as compared to vehicle treated group.
*** p< 0.001, as compared to vehicle treated group.
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cellular changes of the adjacent hepatocytes, mild bile duct
proliferation and intra-acinar inﬂammatory cell inﬁltrates. Li-
ver section from Metformin control group 5 shows the normal
architecture of the liver, no necrosis was observed (Fig. 1).
4. Discussion
It is a well known fact that liver cancer is the most important
epidemic disease in the world which requires immediate atten-
tion. Limited treatment options and poor treatment make
HCC one of the leading causes of death (Ei-Serag and Mason,
1999). DENA is reported to be a hepatotoxin and hepatocar-
cinogenic agent. In the present study, DENA induced hepato-
cellular damage is clearly evidenced by the marked elevation in
serum SGPT, SGOT, GGTP and ALP and a decreased level of
glucose in the liver tissue, These biochemical marker enzymes
are indicators of tumor response (Thirunavukkarasu and Sak-
thisekaran, 2003). SGPT, SGOT, GGTP, ALP and decreased
level of glucose serve as markers of liver damage and mecha-
nisms of neoplastic process. It has been studied that serum
GGTP and ALP levels increase linearly with tumor mass (Carr
et al., 2011). Serum GGTP levels increased linearly with in-
creases in small tumor mass, ALP levels are elevated in associ-
ation with small tumors and further increases with increasing
tumor mass (Pancoska et al., 2011). ALP is used as a speciﬁc
tumor marker during diagnosis in the early detection of cancer.
It is well established that (ALT) level signiﬁes the presence of
active disease and increases risk, particularly if the ALT is per-
sistently or intermittently elevated over the years (Sherman,
2009).Metformin does not scavenge O2 radicals, but is able to re-
act with OH radical. Their results obtained with an in vitro
model allow assuming that Metformin, at a molecular level,
is not a very good scavenger of ROS. Consequently, it seems
that Metformin would certainly exert its in vivo antioxidant
activity by different pathways other than the simple free radi-
cal scavenging action, such as increasing the antioxidant en-
zyme activities, decreasing the markers of lipid peroxidation
and inhibiting the formation of advanced glycation end prod-
ucts (Khouri et al., 2004). Metformin therapy can enhance the
response of patients to DNA damaging agents (chemotherapy
and radiation therapy) because of their extended arrest in the S
phase. Metformin also enhances RTK inhibitor and anti-
EGFR treatment response, because of its action on EGFR
and P-MAPK effects (Wang et al., 2008).
Metformin at a dose of 125 mg/kg restored the levels of
ALP, SGPT, SGOT and GGTP. A well documented fact is
that the levels of SGPT and SGOT increase in HCC (Ramana-
than et al., 2011). An increased GGTP activity is found in the
preneoplastic foci that enhances cell proliferation and in-
creases tumor promotion (Lucier et al., 1991). The GGTP level
elevated signiﬁcantly in the disease control group as compared
to normal control. These results ﬁrmly established the role of
Metformin as a chemopreventive agent in DENA induced
HCC.
Cancer cells require more glucose as energy for survival. In
the present research glucose levels were decreased in disease
control when compared with the normal control group. It indi-
cates that the liver of the disease control group is necrotic and
cell proliferation initiated. Administration of Metformin to
therapeutic group decreased the glucose levels as compared
Normal                     DENA Control
DENA + Metformin Metformin  + DENA
Control Metformin
Figure 1 Photomicrographs (original magniﬁcation 45·) of
histopathological studies of livers of various groups. Normal
architecture of rat liver (Normal group). Necrosis and hepatocel-
lular degeneration of DENA (DENA+Metformin and Metfor-
min + DENA). Lesser damage of hepatocytes and low index of
necrosis in pre and post-treated group control Metformin
(125 mg/kg) treated group.
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for energy production and utilization, indirectly suggesting
its chemopreventive role in the treatment of HCC.
The development of HCC has also been associated with dis-
orders in plasma lipid and lipoprotein metabolism (Jiang et al.,
2006). Cancer development is associated with alterations in li-
pid metabolism, affecting cellular function and growth (Das
et al., 1998). The development of hepatocyte nodules in rat li-
ver is associated with changes in lipid parameters and oxida-
tive status (Abel et al., 2009). Alterations in lipid proﬁles in
malignant tissue are of importance due to their effect on mem-
brane integrity, ﬂuidity and regulation of cellular processes re-
lated to growth and cell survival (Bartsch et al., 1999; Tapiero
et al., 2002).
The increase in cholesterol level increases the membrane
ﬂuidity, regulates membrane permeability and alters internal
viscosity and also the internal chemical composition. In the
present research it was observed that Metformin maintained
the lipid proﬁle, hence it can be suggested that Metformin
may play the role in inhibition of carcinoma progression.
AFP is a serum protein that is detected in elevated concen-
tration in conditions like hepatocellular carcinoma. It is similar
in size, structure and amino acid composition to serum albu-
min, but it is detectable only in minute amounts in the serum
of normal adults. Elevated serum concentrations of this pro-tein can be achieved in the adult by exposure to hepatocarcin-
ogenic agents. AFP has the high speciﬁcity for
hepatocarcinoma. Its serum concentration conﬁrms hepato-
carcinoma and the diagnosis of tumor response to therapy.
In the present study, serum AFP level of DENA treated
rats showed a signiﬁcant increase compared to that of control
group, proving the occurrence of premalignant liver changes in
DENA treated rats. The elevation of serum AFP in HCC is
well documented by many researchers (Borges et al., 2005;
Yeo et al., 2006). Co-treatment with Metformin signiﬁcantly
reduced serum AFP.
Histopathological examination of the disease control group
showed central veins surrounded by extensive necrosis and
inﬂammation. The tumor cells resembling hepatocytes showed
pleomorphism and were seen as 2–8 cell wide trabeculae that
were separated by endothelial lined sinusoidal spaces. But in
therapeutic group mild bile duct proliferation with no central
veins, observation in the photograph suggests the tumor sup-
pressing nature of Metformin at a dose of 125 mg/kg.
Further, as proved by Donadon et al. (2010), Nkontchou
et al. (2011) and Chen et al. (2012) on humans a chemopreven-
tive role of Metformin in cirrhosis, and thyroid cancer with
existing anticancer drugs. Nowhere the biochemical mecha-
nism of this drug was discussed. In the present study it is an
effort to correlate the biochemical mechanism of Metformin
as a chemopreventive agent.
The above result indicates that Metformin might be used as
chemopreventive by decreasing the level of glucose in the can-
cer cell. Metformin is an antidiabetic drug which decreases glu-
coneogenesis process through increase in glucose utilization in
the body and decrease in hepatic glucose production. In cancer
cells the gluconeogenesis process is increased. Cancer is a pro-
cess of non recognized cells in the body with some markers,
where a decrease in the level of glucose may activate the im-
mune response to retard/inhibit the growth of tumor cells.
5. Conclusion
The above observations suggest that Metformin an antidia-
betic drug can possess chemopreventive action. Metformin at
reduced dose (125 mg/kg) suppresses the tumors and decreases
the biochemical marker which is elevated in HCC. This will
open new perspectives that Metformin is a chemopreventive
compound to prevent, slow or treat the occurrence of liver
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